Let's talk
Contact us

Plasma Protein Binding Assay (mouse, rat, dog, monkey, human)


Readout: % Binding, % Remaining at time point, % Recovery

Controls:  Phenacetine, Quinidine, Warfarin


Assay Description:                                           

Working solutions (1 mM in DMSO) are prepared for each test and control compound. The dosing solutions are prepared by diluting the working solutions to 5 µM in plasma.

The dialysis plate (RED device)⁵ is prepared by adding buffer to one chamber of the RED device and dosing solution to the other chamber. The plate is sealed with an adhesive film and incubated at 37 °C while shaking for 5 h. Equal volumes of post dialysis samples are removed from both the plasma and the buffer chambers in separate microcentrifuge tubes and equal volumes (50 µL) of fresh phosphate buffer and plasma are added to the tubes, respectively.

Plasma samples are diluted 5-fold and then all samples are treated with quenching solution (terfenadine/tolbutamide in methanol/ACN). Sample mixtures are then centrifuged and the supernatant is removed for LC-MS/MS analysis.

To assess plasma stability, aliquots of dosing solution are stored at 4 °C (t = 0 h sample) and at 37 °C for 5 h (t = 5 h sample).  Following incubation, aliquots are removed for LC-MS/MS analysis.

The MS detection is performed by using a SCIEX API 4000 Q trap instrument. Each compound is analyzed by reversed phase HPLC using a Kinetex 2.6µ C18 100Å column (3.0 mm X 30 mm, Phenomenex). Mobile phase – Solvent A: water with 0.1% formic acid, solvent B: ACN with 0.1% formic acid. The amount of parent compound is determined on the basis of the peak area ratio (compound area to IS area) for each time point.


Data Analysis:

The calculation of percentage binding is determined using the following equations:

Binding % = (Cpe – Cb) / Cpe x 100

% Stability of test compound = (Conc. of stability sample / Conc. of time zero sample) x 100

% Recovery = (Cpe + Cb) / Conc. of stability sample x 100


Cpe =    Concentration of test compound in plasma at equilibrium

Cb =      Concentration of test compound in buffer at equilibrium




ACN                         Acetonitrile

DMSO                     Dimethylsulfoxide

HPLC                       High-performance liquid chromatography

LC                             Liquid chromatography

MS                           Mass spectrometry

PPB                          Plasma Protein Binding

RED                         Rapid Equilibrium Dialysis



  1. Trainor, G. L.; “The importance of plasma protein binding in drug discovery“; Expert Opin. Drug Discov. 2, 51, (2007).

in vitro adme assay plasma protein binding


How can we meet your drug discovery and development needs?

Contact Us